Patents by Inventor Duane D. Miller

Duane D. Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10314797
    Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: June 11, 2019
    Assignee: University of Tennessee Research Foundation
    Inventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Yali He
  • Patent number: 10301285
    Abstract: The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: May 28, 2019
    Assignees: GTX, INC., UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Duane D. Miller, Jianjun Chen, James T. Dalton, Chien-Ming Li, Sunjoo Ahn, Wei Li
  • Publication number: 20190144387
    Abstract: This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
    Type: Application
    Filed: September 5, 2018
    Publication date: May 16, 2019
    Applicant: University of Tennessee Research Foundation
    Inventors: Ramesh NARAYANAN, Duane D. MILLER, Thamarai PONNUSAMY, Dong-Jin HWANG, Yali HE
  • Publication number: 20190092755
    Abstract: The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.
    Type: Application
    Filed: January 16, 2018
    Publication date: March 28, 2019
    Inventors: Duane D. MILLER, Jianjun CHEN, James T. DALTON, Chien-Ming LI, Sunjoo AHN, Wei LI
  • Publication number: 20190060280
    Abstract: This invention is directed to selective androgen receptor degrader (SARD) compounds pharmaceutical compositions and uses thereof in treating early prostate cancer, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
    Type: Application
    Filed: May 16, 2018
    Publication date: February 28, 2019
    Applicant: University of Tennessee Research Foundation
    Inventors: Ramesh NARAYANAN, Duane D. MILLER, Thamarai PONNUSAMY, Dong-Jin HWANG, Yali HE
  • Publication number: 20190055192
    Abstract: This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject including, inter alia, hormone-related conditions, bone-related disorders, and muscle wasting diseases and/or disorders.
    Type: Application
    Filed: July 20, 2018
    Publication date: February 21, 2019
    Inventors: James T. Dalton, Duane D. Miller
  • Publication number: 20190040000
    Abstract: This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other 5 hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
    Type: Application
    Filed: October 5, 2018
    Publication date: February 7, 2019
    Inventors: Ramesh Narayanan, Duane D. MILLER, Thamarai PONNUSAMY, Dong-Jin HWANG, Charles B. DUKE, Christopher C. COSS, Amanda JONES, James T. DALTON
  • Publication number: 20190015387
    Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
    Type: Application
    Filed: May 16, 2018
    Publication date: January 17, 2019
    Applicant: University of Tennessee Research Foundation
    Inventors: Ramesh NARAYANAN, Duane D. MILLER, Thamarai PONNUSAMY, Dong-Jin HWANG, Yali HE
  • Publication number: 20180360805
    Abstract: This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
    Type: Application
    Filed: May 16, 2018
    Publication date: December 20, 2018
    Applicants: GTx, Inc., University of Tennessee Research Foundation
    Inventors: Ramesh NARAYANAN, Duane D. MILLER, Thamarai PONNUSAMY, Dong-Jin HWANG, Yali HE, Jayaprakash PAGADALA, Charles B, DUKE, Christopher C. COSS, James T. DALTON
  • Patent number: 10155728
    Abstract: The present invention relates to colchicine-binding site compounds having anti-cancer activity, compositions comprising the same, and their use for treating various forms of cancer.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: December 18, 2018
    Assignees: GTX INC., UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Yan Lu, James T Dalton, Wei Li, Duane D Miller
  • Publication number: 20180325872
    Abstract: The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.
    Type: Application
    Filed: July 12, 2018
    Publication date: November 15, 2018
    Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: JIN Wang, Jianjun Chen, Duane D. Miller, Wei Li
  • Patent number: 10093613
    Abstract: This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: October 9, 2018
    Assignees: GTX, INC., UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Charles B. Duke, Christopher C. Coss, Amanda Jones, James T. Dalton
  • Publication number: 20180273487
    Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
    Type: Application
    Filed: March 16, 2018
    Publication date: September 27, 2018
    Applicant: University of Tennessee Research Foundation
    Inventors: Ramesh NARAYANAN, Duane D. MILLER, Thamarai PONNUSAMY, Dong-Jin HWANG, Yali HE
  • Publication number: 20180273470
    Abstract: This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject including, inter alia, a muscle wasting disease and/or disorder such as Duchenne muscular dystrophy or Becker muscular dystrophy.
    Type: Application
    Filed: February 2, 2018
    Publication date: September 27, 2018
    Inventors: Ramesh NARAYANAN, Thamarai PONNUSAMY, James T. Dalton, Duane D. MILLER
  • Patent number: 10053418
    Abstract: This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject including, inter alia, a muscle wasting disease and/or disorder such as Duchenne muscular dystrophy or Becker muscular dystrophy.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: August 21, 2018
    Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: James T. Dalton, Duane D. Miller
  • Patent number: 10035763
    Abstract: This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: July 31, 2018
    Assignee: GTX, INC.
    Inventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Jayaprakash Pagadala, Charles B. Duke, Christopher C. Coss, James T. Dalton, Yali He
  • Patent number: 10022356
    Abstract: The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: July 17, 2018
    Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Jin Wang, Jianjun Chen, Duane D. Miller, Wei Li
  • Patent number: 10017471
    Abstract: This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: July 10, 2018
    Assignees: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, GTX, INC.
    Inventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Jayaprakash Pagadala, Charles B. Duke, Christopher C. Coss, James T. Dalton, Yali He
  • Patent number: 9981915
    Abstract: The present invention relates to colchicine-binding site compounds having anti-cancer activity, compositions comprising the same, and their use for treating various forms of cancer.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: May 29, 2018
    Assignees: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, GTx, INC
    Inventors: Yan Lu, James T Dalton, Wei Li, Duane D Miller
  • Publication number: 20180118693
    Abstract: The present invention relates to colchicine-binding site compounds having anti-cancer activity, compositions comprising the same, and their use for treating various forms of cancer.
    Type: Application
    Filed: December 29, 2017
    Publication date: May 3, 2018
    Applicants: GTx, Inc., UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Yan Lu, James T. Dalton, Wei Li, Duane D. Miller